MedTrace Logo

Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

NCT03349008 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2017-11-21

No results posted yet for this study

Summary

This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium glycyrrhizinate and entecavir in combination, while the other half will receive a placebo and entecavir.

Conditions

Interventions

DRUG

Entecavir

Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based

DRUG

Magnesium Isoglycyrrhizinate

Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based

DRUG

Diammonium Glycyrrhizinate

Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based

DRUG

Magnesium Isoglycyrrhizinate Placebo

Magnesium Isoglycyrrhizinate Injection Placebo

DRUG

Diammonium Glycyrrhizinate Placebo

Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo

Sponsors & Collaborators

  • Cttq

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-25
Primary Completion
2019-12-31
Completion
2020-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03349008 on ClinicalTrials.gov